-+ 0.00%
-+ 0.00%
-+ 0.00%

Wave Life Sciences initiates Phase 2a INLIGHT trial of WVE-007 obesity drug candidate

PUBT·06/24/2026 12:31:50
Listen to the news
Wave Life Sciences initiates Phase 2a INLIGHT trial of WVE-007 obesity drug candidate
  • Wave Life Sciences initiated the Phase 2a multidose portion of the placebo-controlled INLIGHT trial for WVE-007 in obesity with comorbidities.
  • Early Phase 1 findings have already been presented, showing improved body composition with fat loss while maintaining muscle, supporting infrequent dosing.
  • The Phase 2a readout is expected in the future, designed to clarify whether the drug can deliver meaningful weight loss and cardiometabolic benefits.
  • Wave plans additional Phase 2 studies in 2H 2026 to test WVE-007 alongside incretin therapies, including post-incretin maintenance use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240830PRIMZONEFULLFEED9751715) on June 24, 2026, and is solely responsible for the information contained therein.